Marcello Cattani

#ClimateChange is impacting global health, particularly those more vulnerable to the threats of #airpollution, such as people with respiratory conditions. At Chiesi, we strongly believe that #patients should not have to shoulder the burden of environmental responsibility when considering treatment options that affect their #health. Learn more by watching the episode “How Redesigning Inhalers Could Reduce Their Environmental Impact” sponsored by Chiesi and produced by BBC StoryWorks: https://lnkd.in/dCTQNiez #EarthDay #ActionOverWords #TheClimateAndUs

234

Stay up to date on the latest developments of Life Sciences news in Italy and gain valuable insights from our team in the latest issue of our newsletter. Covering a wide spectrum of practice areas, highlights include: • Regulatory  • WCC/Compliance  • IP  • Data, Privacy & Cybersecurity  • Product Liability  • Antitrust Click the link below to read our #LifeSciences #newsletter #DLAPiperItaly

35

Yesterday our longstanding partner Verona Pharma achieved a pivotal milestone with the #FDA approval of Ohtuvayre™, previously known as ensifentrine, the first inhaled product with a novel mechanism of action available for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in more than 20 years. This is a significant step forward for the millions of COPD patients who have sought better treatment options to manage the daily symptoms of this disease. For Ligand this is also an important milestone. It’s the second FDA approval within our royalty portfolio in two weeks, and the eighth regulatory approval since 2023. We have earned a $5.8 million milestone payment upon FDA approval of Ohtuvayre. We will also earn an additional $13.8 million upon the commercial launch of Ohtuvayre, which is expected to occur during the third quarter of 2024, and a low single-digit royalty on worldwide net sales. With Ohtuvayre, we now have 11 key commercial stage products driving our financial performance and a portfolio of more than 100 additional programs at various stages of development. Read our announcement on the Ohtuvayre approval here: https://bit.ly/4cfTk9S

36

Behaviorally's Crispin Beale (Group President) will be speaking TOMORROW at #ContaminAzioni 2024 with Elma Research Italy in Milan! Join us to explore the evolution of market research and gain valuable insights into the pharmaceutical sector! Register here: https://hubs.ly/Q02wcBCZ0 #milan #conference #Elmaresearch #insights #insightsindustry #marketresearch #wearebehaviorally #behaviorallyinc

21

1 commento